NDUFAF4
ENSG00000123545
Target class
Enzyme
Chromosome
6
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFAF4
- Gene name
- NADH:ubiquinone oxidoreductase complex assembly factor 4
- Gene symbol
- NDUFAF4
- Previous gene symbols
- C6orf66
- Protein name
- NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 4 (Hormone-regulated proliferation-associated protein of 20 kDa)
- HSPC125
- bA22L21.1
- My013
- HRPAP20
- Gene biotype
- Protein coding
- Gene family
- Mitochondrial respiratory chain complex assembly factors
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 31.3
- Tissue specificity (Gini)
- 0.196
- Tissue specificity (tau)
- 0.562
- KEGG gene identifiers
- hsa:29078
- Reactome pathways
- R-HSA-6799198
- Protein interaction confidence
- 0.919196
- Protein interaction partners
- 56
- End position
- 96897894
- Start position
- 96889313
- Chromosome
- 6
- Strand
- Reverse
- Mitochondrion . Membrane
- Lipid-anchor .
- Mitochondria
Publication evidence
- PubMed 18179882
- Tissue specificity (tau)
- 0.562107
- Expression inequality (Gini)
- 0.196108
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 31.3
- Brain - Cerebellar Hemisphere
- 30.75
- Brain - Cerebellum
- 24.33
- Heart - Left Ventricle
- 20
- Heart - Atrial Appendage
- 19.96
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)31.3
- Brain - Cerebellar Hemisphere30.75
- Brain - Cerebellum24.33
- Heart - Left Ventricle20
- Heart - Atrial Appendage19.96
- Cells - EBV-transformed lymphocytes19.88
- Artery - Tibial19.28
- Esophagus - Muscularis18.63
- Colon - Sigmoid18.37
- Brain - Cortex17.84
- Brain - Anterior cingulate cortex (BA24)17.81
- Muscle - Skeletal17.45
- Brain - Hypothalamus17.03
- Kidney - Medulla16.76
- Esophagus - Gastroesophageal Junction16.56
- Artery - Coronary16.36
- Brain - Caudate (basal ganglia)15.19
- Brain - Nucleus accumbens (basal ganglia)15.1
- Bladder15
- Colon - Transverse14.87
- Adipose - Visceral (Omentum)14.55
- Brain - Substantia nigra13.73
- Thyroid13.7
- Cells - Cultured fibroblasts13.52
- Cervix - Ectocervix13.38
And 29 more, listed on the interactive page.
- GO:0032981
- GO:0051607
- GO:0005739
- GO:0005743
- GO:0031966
Molecular functions
- GO:0005515
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor